慢性心力衰竭患者血清MYO、cTnI、CK-MB水平变化及对疗效的预测价值  

Level changes of MYO,cTnI and CK-MB in patients with chronic heart failure and their clinical significance

作　　者：马蓉 张春有 MA Rong;ZHANG Chunyou(Clinical Laboratory,Xinxiang Traditional Chinese Medicine Hospital,Xinxiang,Henan 453003,China)

机构地区：[1]河南省新乡市中医院检验科,453003

出　　处：《淮海医药》2024年第4期355-359,共5页Journal of Huaihai Medicine

摘　　要：目的:探讨慢性心力衰竭(CHF)患者血清肌红蛋白(MYO)、肌钙蛋白Ⅰ(cTnI)、肌酸激酶同工酶(CK-MB)水平变化及与心功能的相关性,并分析其对疗效的预测价值。方法:选取2021年7月—2023年7月某院收治的92例CHF患者作为研究组,另选取同期健康体检者92例作为对照组。比较2组血清MYO、cTnI、CK-MB水平,分析血清MYO、cTnI、CK-MB水平与心功能分级相关性;比较不同疗效患者血清MYO、cTnI、CK-MB水平,分析其水平与CHF患者疗效的关系,绘制受试者工作曲线(ROC),评价血清MYO、cTnI、CK-MB水平对CHF患者疗效的预测价值。结果:研究组血清MYO、cTnI、CK-MB水平高于对照组,差异有统计学意义(P<0.05)。随着NYHA心功能分级增加,血清MYO、cTnI、CK-MB水平呈上升趋势(P<0.05);Spearman相关分析显示,血清MYO、cTnI、CK-MB水平与NYHA心功能分级呈正相关关系(r=0.448、0.462、0.537,P均<0.05)。无效者血清MYO、cTnI、CK-MB水平高于有效者(P<0.05);多因素Logistic回归分析显示,治疗7 d后血清MYO、cTnI、CK-MB水平均为CHF患者疗效的影响因素(P<0.05);血清MYO、cTnI、CK-MB水平对CHF患者疗效预测价值的AUC分别为0.801、0.769、0.829,联合预测的AUC为0.963。结论:CHF患者血清MYO、cTnI、CK-MB水平升高,且与心功能分级呈正相关关系,联合检测其水平对疗效具有一定预测价值,可作为预测疗效的潜在指标。Objective:To investigate the correlation between serum myoglobin(MYO),troponin I(cTnI)and creatine kinase isoenzyme(CK-MB)levels and cardiac function in patients with chronic heart failure(CHF),and to analyze their predictive value for therapeutic effect.Methods:92 CHF patients admitted to a hospital from July 2021 to July 2023 were selected as a study group,and another 92 healthy volunteers in the same period were recruited as a control group.The correlation between serum MYO,cTnI,CK-MB levels and cardiac function grading in the two groups were compared.Serum MYO,cTnI,and CK-MB levels of those with different efficacies were compared and analyzed for their correlation with the efficacy of the treatment,ROC was plotted and their predictive value for the efficacy was assessed.Results:The levels of serum MYO,cTnI,and CK-MB in the study group were higher than those in the control group(P<0.05).As the NYHA classification of cardiac function increased,the levels of serum MYO,cTnI,and CK-MB showed an upward trend(P<0.05).The levels of serum MYO,cTnI,and CK-MB were positively correlated with the NYHA classification of cardiac function(r=0.448,0.462,0.537,all P<0.05).The levels of serum MYO,cTnI,and CK-MB in the ineffective group were higher than those in the effective group(P<0.05).The levels of serum MYO,cTnI,and CK-MB after 7 days of treatment were independent factors affecting the efficacy(P<0.05).The AUCs of serum MYO,cTnI,CK-MB alone and in combination for predicting the efficacy were 0.801,0.769,0.829,and 0.963,respectively,and the AUC of combined prediction was greater than that of single index prediction(P<0.05).Conclusion:The levels of serum MYO,cTnI,and CK-MB in patients with CHF are elevated and positively correlated with the classification of cardiac function.Combined detection of their levels has certain predictive value for therapeutic efficacy and may serve as a potential indicator for predicting therapeutic efficacy.

关 键 词：慢性心力衰竭 肌红蛋白 肌钙蛋白Ⅰ 肌酸激酶同工酶 预测价值 

分 类 号：R541.6[医药卫生—心血管疾病]